Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective Trial
Von Hippel–Lindau disease (VHL) is a hereditary disorder associated with malignant tumors including clear cell renal cell carcinoma (ccRCC). Partial nephrectomy is complicated by multilocular tumor occurrence and a high recurrence rate. The aim of this study was to evaluate the potential of stereota...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/20/5069 |
| _version_ | 1797474499807936512 |
|---|---|
| author | Simon Kirste Alexander Rühle Stefan Zschiedrich Wolfgang Schultze-Seemann Cordula A. Jilg Elke Neumann-Haefelin Simon S. Lo Anca-Ligia Grosu Emily Kim |
| author_facet | Simon Kirste Alexander Rühle Stefan Zschiedrich Wolfgang Schultze-Seemann Cordula A. Jilg Elke Neumann-Haefelin Simon S. Lo Anca-Ligia Grosu Emily Kim |
| author_sort | Simon Kirste |
| collection | DOAJ |
| description | Von Hippel–Lindau disease (VHL) is a hereditary disorder associated with malignant tumors including clear cell renal cell carcinoma (ccRCC). Partial nephrectomy is complicated by multilocular tumor occurrence and a high recurrence rate. The aim of this study was to evaluate the potential of stereotactic body radiotherapy (SBRT) as an alternative treatment approach in VHL patients with multiple ccRCC. Patients with VHL and a diagnosis of ccRCC were enrolled. SBRT was conducted using five fractions of 10 Gy or eight fractions of 7.5 Gy. The primary endpoint was local control (LC). Secondary endpoints included alteration of renal function and adverse events. Seven patients with a total of eight treated lesions were enrolled. Median age was 44 years. Five patients exhibited multiple bilateral kidney cysts in addition to ccRCC. Three patients underwent at least one partial nephrectomy in the past. After a median follow-up of 43 months, 2-year LC was 100%, while 2-year CSS, 2-year PFS and 2-year OS was 100%, 85.7% and 85.7%, respectively. SBRT was very well tolerated with no acute or chronic toxicities grade ≥ 2. Mean estimated glomerular filtration rate (eGFR) at baseline was 83.7 ± 13.0 mL/min/1.73 m<sup>2</sup>, which decreased to 76.6 ± 8.0 mL/min/1.73 m<sup>2</sup> after 1 year. Although the sample size was small, SBRT resulted in an excellent LC rate and was very well tolerated with preservation of kidney function in patients with multiple renal lesions and cysts. |
| first_indexed | 2024-03-09T20:31:56Z |
| format | Article |
| id | doaj.art-4834f59f468b4e97975eed93f98b3f79 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T20:31:56Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-4834f59f468b4e97975eed93f98b3f792023-11-23T23:21:26ZengMDPI AGCancers2072-66942022-10-011420506910.3390/cancers14205069Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective TrialSimon Kirste0Alexander Rühle1Stefan Zschiedrich2Wolfgang Schultze-Seemann3Cordula A. Jilg4Elke Neumann-Haefelin5Simon S. Lo6Anca-Ligia Grosu7Emily Kim8Department of Radiation Oncology, Medical Center—University of Freiburg, Faculty of Medicine, 79106 Freiburg, GermanyDepartment of Radiation Oncology, Medical Center—University of Freiburg, Faculty of Medicine, 79106 Freiburg, GermanyRenal Division, Department of Internal Medicine, Bürgerspital Solothurn, 4500 Solothurn, SwitzerlandDepartment of Urology, Medical Center—University of Freiburg, Faculty of Medicine, 79106 Freiburg, GermanyDepartment of Urology, Medical Center—University of Freiburg, Faculty of Medicine, 79106 Freiburg, GermanyRenal Division, Department of Medicine, Medical Center—University of Freiburg, Faculty of Medicine, 79106 Freiburg, GermanyDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, WA 98195, USADepartment of Radiation Oncology, Medical Center—University of Freiburg, Faculty of Medicine, 79106 Freiburg, GermanyDepartment of Radiation Oncology, Medical Center—University of Freiburg, Faculty of Medicine, 79106 Freiburg, GermanyVon Hippel–Lindau disease (VHL) is a hereditary disorder associated with malignant tumors including clear cell renal cell carcinoma (ccRCC). Partial nephrectomy is complicated by multilocular tumor occurrence and a high recurrence rate. The aim of this study was to evaluate the potential of stereotactic body radiotherapy (SBRT) as an alternative treatment approach in VHL patients with multiple ccRCC. Patients with VHL and a diagnosis of ccRCC were enrolled. SBRT was conducted using five fractions of 10 Gy or eight fractions of 7.5 Gy. The primary endpoint was local control (LC). Secondary endpoints included alteration of renal function and adverse events. Seven patients with a total of eight treated lesions were enrolled. Median age was 44 years. Five patients exhibited multiple bilateral kidney cysts in addition to ccRCC. Three patients underwent at least one partial nephrectomy in the past. After a median follow-up of 43 months, 2-year LC was 100%, while 2-year CSS, 2-year PFS and 2-year OS was 100%, 85.7% and 85.7%, respectively. SBRT was very well tolerated with no acute or chronic toxicities grade ≥ 2. Mean estimated glomerular filtration rate (eGFR) at baseline was 83.7 ± 13.0 mL/min/1.73 m<sup>2</sup>, which decreased to 76.6 ± 8.0 mL/min/1.73 m<sup>2</sup> after 1 year. Although the sample size was small, SBRT resulted in an excellent LC rate and was very well tolerated with preservation of kidney function in patients with multiple renal lesions and cysts.https://www.mdpi.com/2072-6694/14/20/5069stereotactic body radiotherapySBRTstereotactic ablative radiotherapySABRrenal cell carcinomavon Hippel–Lindau disease |
| spellingShingle | Simon Kirste Alexander Rühle Stefan Zschiedrich Wolfgang Schultze-Seemann Cordula A. Jilg Elke Neumann-Haefelin Simon S. Lo Anca-Ligia Grosu Emily Kim Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective Trial Cancers stereotactic body radiotherapy SBRT stereotactic ablative radiotherapy SABR renal cell carcinoma von Hippel–Lindau disease |
| title | Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective Trial |
| title_full | Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective Trial |
| title_fullStr | Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective Trial |
| title_full_unstemmed | Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective Trial |
| title_short | Stereotactic Body Radiotherapy for Renal Cell Carcinoma in Patients with Von Hippel–Lindau Disease—Results of a Prospective Trial |
| title_sort | stereotactic body radiotherapy for renal cell carcinoma in patients with von hippel lindau disease results of a prospective trial |
| topic | stereotactic body radiotherapy SBRT stereotactic ablative radiotherapy SABR renal cell carcinoma von Hippel–Lindau disease |
| url | https://www.mdpi.com/2072-6694/14/20/5069 |
| work_keys_str_mv | AT simonkirste stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial AT alexanderruhle stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial AT stefanzschiedrich stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial AT wolfgangschultzeseemann stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial AT cordulaajilg stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial AT elkeneumannhaefelin stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial AT simonslo stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial AT ancaligiagrosu stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial AT emilykim stereotacticbodyradiotherapyforrenalcellcarcinomainpatientswithvonhippellindaudiseaseresultsofaprospectivetrial |